BioSante Pharmaceuticals to Present at UBS Global Life Sciences Conference
September 25 2006 - 8:00AM
Business Wire
BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that
Stephen M. Simes, the Company's president and chief executive
officer, will present a corporate and clinical overview of the
Company at the UBS Global Life Sciences Conference, taking place at
the Grand Hyatt Hotel in New York City, on September 28, 2006. Mr.
Simes' presentation is scheduled for 2:30 p.m. EDT. A live audio
webcast of BioSante's presentation may be accessed at
http://www.biosantepharma.com/investors/events.html and a replay
will be available at the same link for 90 days. About BioSante
Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone
therapy products to treat both men and women. These hormone therapy
products are gel formulations for transdermal administration that
deliver bioidentical estradiol and testosterone. BioSante's lead
products include Bio-E-Gel(R) (transdermal estradiol gel) for the
treatment of women with menopausal symptoms, and LibiGel(R)
(transdermal testosterone gel) for the treatment of female sexual
dysfunction (FSD). A Bio-E-Gel new drug application (NDA) was
submitted to the FDA in the first quarter 2006. The current market
in the U.S. for estrogen and testosterone products is approximately
$2.5 billion. The transdermal gel formulations used in the women's
gel products are licensed by BioSante from Antares Pharma Inc. The
company also is developing its calcium phosphate nanotechnology
(CaP) for novel vaccines, including avian flu and biodefense
vaccines for toxins such as anthrax and ricin, and drug delivery
systems. Additional information is available online at:
www.biosantepharma.com. BioSante Pharmaceuticals, Inc. (Amex:BPA)
today announced that Stephen M. Simes, the Company's president and
chief executive officer, will present a corporate and clinical
overview of the Company at the UBS Global Life Sciences Conference,
taking place at the Grand Hyatt Hotel in New York City, on
September 28, 2006. Mr. Simes' presentation is scheduled for 2:30
p.m. EDT. A live audio webcast of BioSante's presentation may be
accessed at http://www.biosantepharma.com/investors/events.html and
a replay will be available at the same link for 90 days. About
BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of
hormone therapy products to treat both men and women. These hormone
therapy products are gel formulations for transdermal
administration that deliver bioidentical estradiol and
testosterone. BioSante's lead products include Bio-E-Gel(R)
(transdermal estradiol gel) for the treatment of women with
menopausal symptoms, and LibiGel(R) (transdermal testosterone gel)
for the treatment of female sexual dysfunction (FSD). A Bio-E-Gel
new drug application (NDA) was submitted to the FDA in the first
quarter 2006. The current market in the U.S. for estrogen and
testosterone products is approximately $2.5 billion. The
transdermal gel formulations used in the women's gel products are
licensed by BioSante from Antares Pharma Inc. The company also is
developing its calcium phosphate nanotechnology (CaP) for novel
vaccines, including avian flu and biodefense vaccines for toxins
such as anthrax and ricin, and drug delivery systems. Additional
information is available online at: www.biosantepharma.com.
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Biosante Pharma (AMEX:BPA)
Historical Stock Chart
From Sep 2023 to Sep 2024